is tirzepatide still in shortage FDA reconsidering its decision to take off its drug list Some patients now turn to
Description
The European Medicines Agency (EMA) recently launched an investigation into Novo Nordisk's GLP-1 treatments, including Saxenda (ingredient: liraglutide), Ozempic (ingredient: semaglutide), and Wegovy (ingredient: semaglutide), after the Icelandic Medicines Agency reported two adverse events of suicidal or self-harming behavior in patients taking Saxenda and Ozempic

To see how these compare, let's look at the data from different trials
Int J Dev Neurosci novembre

Required documentation (as of April 2026): BMI documentation
